Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

BACKGROUND: More and more evidence indicates sodium-glucose co-transporter 2 inhibitors (SGLT2is) may display clinical benefits for heart failure with preserved ejection fraction (HFpEF). However, the mechanisms of the action remain unclear. METHODS: A systematic pharmacology-based strategy was appl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Bo, Liang, Yi, Gu, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188076/
https://www.ncbi.nlm.nih.gov/pubmed/35689186
http://dx.doi.org/10.1186/s12872-022-02693-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188076/
https://www.ncbi.nlm.nih.gov/pubmed/35689186
http://dx.doi.org/10.1186/s12872-022-02693-8

Ejemplares similares